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Transfusion of autologous leukocytes after prolonged storage has been proposed as a means of rejuvenating the
immune system of older individuals. The rationale for this approach is that age related immune decline is
associated with a diminished pool of naïve T cells following atrophy of the thymus and reduction in thymic output.
The presence of high levels of naïve T cells within the blood of young individuals could provide a boost to the
immune system of an older “self” through a rejuvenation of the naïve T cell pool. However what remains
unresolved is whether the cells could be incorporated effectively into the T cell pool of the host and whether
effectors could be generated. Using CD45 congenic mice in our experiments we show that the transfusion of
young donor cells into older congenic host animals leads to their successful incorporation into the peripheral T cell
pool. When the recipients were challenged with influenza virus, specific effector CD8 cells were generated which
were of both host and donor origin. We found no relationship between the number of responder cells of donor
origin at the time of assay and the number of cells injected.
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Influenza is an infectious disease of limited duration in
young adults with an optimal functioning immune sys-
tem. It is normally associated with a sudden onset and
symptoms which can include fever, cough, nasal conges-
tion, and aching joints. In older individuals, whose im-
mune system shows a degree of age-related dysfunction,
influenza infection has serious consequences including
an increased risk of mortality and a greater likelihood of
hospitalization, but also acts as a trigger for functional
decline [1-3].
Evidence for this decline, often termed immunosene-
scence, has been derived from data gained from epi-
demiological studies, results from vaccine trials and
laboratory investigations, and observations by clinicians.
Epidemiological studies reveal that the prevalence of dis-
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reproduction in any medium, provided the orurinary tract infections, considerably increases with age.
Moreover the ability to control persistent viral infection
also diminishes as we age [2,4,5]. Murine models have
shown that age associated immune decline has multiple
causes, which include a much smaller pool of naïve T
cells following reduced output from the thymus as a
consequence of age associated thymic atrophy, dimin-
ished functional performance of the peripheral T lym-
phocytes, specifically the CD8 cells, and the presence of
holes in the repertoire arising from the loss of some
clonotypes [6-10]. These changes may be central to the
issue of making an effective response to influenza vi-
ruses, since previous studies have shown the critical role
of CD8 cells in the control of viral infections. Early stu-
dies identified that cloned CD8 cells specific for influ-
enza viruses, when transferred into influenza infected
mice, could reduce both lung virus titers, prolong sur-
vival times, [11] and in addition could protect mice from
lethal infections [12].
Improvements in the CD8 T cell pool of old animals,
can be achieved by increasing the number of reactive cells
through adoptive transfer. This was tested in a recentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from young animals, and transfused into old animals. The
results revealed that the environment in the old animals
inhibited their clonal expansion during virus infection
[13]. A different approach was taken in experiments to in-
crease specific influenza virus T cell responses, through
providing a larger naïve T cell pool in old animals by re-
versing thymic atrophy using interleukin 7. This rejuven-
ation of the immune system has produced old animals
that show improved responses to influenza viral infection
with much reduced viral loads in the lungs, compared
with age matched controls [14]. One of the issues with
treatment with interleukin 7 is the need for frequent in-
jections [15-17]. Thus, identifying new alternative ap-
proaches to rejuvenate the immune system, specifically
the naïve T cell pool, is an attractive challenge. One option
which has been proposed is to increase the number of
naive T lymphocytes in the peripheral T cell pool by trans-
fusion [18]. This could be achieved by the preservation of
quantities of an individual’s blood leukocytes at a younger
age, which would then be transfused back into them at a
later stage, when the immune system demonstrates some
features of immunosenescence. Such use of autologous
tissue would, of course, negate any problems associated
with rejection. Adoptive transfer of lymphocytes has
already been suggested for the treatment of some viral dis-
eases [19] and cancers [20]. The transfer of syngeneic or
autochthonous T cells from young to old whilst having
been suggested [18] has not been tested.
Two major overlapping issues confront the idea of re-
juvenating an older individual’s immune system by trans-
fusing blood leukocytes stored from when they were
younger. The first is, whether an individual whose im-
mune system is compromised, would be able to provideFigure 1 Flow cytometer dot plot of the naive (CD62Lhi CD44lo) and
CD3+CD8+ (B) in the blood of young donor animals.a suitable environment for any transfused cells to make
an immune response. The second issue is how many leu-
kocytes have to be infused in order to ensure that suffi-
cient specific effectors are generated.
In order to clarify these two major issues, we trans-
ferred blood from young C57BL/6.SJL mice into old
C57BL/6 mice and then vaccinated them against influ-
enza infection (three injections of formalin inactivated
influenza virus A/PR/8 over two weeks) before challenging
them 3 weeks after the last vaccination with live A/PR/8
influenza virus delivered intra-nasally. We transferred
graded amounts of blood into the old animals, and
assessed the quantity of virally specific CD8 T cells by
phenotypic staining.
Peripheral blood constitutes approximately 1-2% of the
total T cell pool and samples taken from blood are often
considered to be representative of the total T cell pool. To
parallel potential future manipulations in the rejuvenation
of the human immune system we have chosen to derive
our donor cells from the blood of young mice.
Results
Young blood leukocyte constituents
Analysis of the blood collected from young animals re-
vealed that the mononuclear leukocyte population
contained 65% CD3+ cells of which 33% were CD8+.
Within the latter population 58% were naive cells with
a phenotype of CD3+CD8+CD44-CD62L+ whilst 16%
had a memory phenotype of CD3+CD8+CD44+CD62L-.
Figure 1 shows flow cytometer dot plots of phenotypes
within the CD4+ and CD8+ subsets. Cell counts on the
blood revealed that there was on average 7.1 × 106 cells
per ml. Mononuclear cells were prepared from the blood
and transfused into recipient older animals. Four groupsmemory (CD62Llo CD44hi) cells which were CD3+CD4+ (A) or
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but saline vehicle alone; group 2 received 7.1 × 105 cells
equivalent to 100 μl of blood; group 3 received 1.8 × 106
cells equivalent to 250 μl of blood; and groups 4 re-
ceived 3.5 × 106 cells equivalent to 500 μl of blood.
Table 1 shows the numbers and phenotypes of popula-
tions of cells received by each group. These cells were
transferred into the old host and a schematic of the pro-
cedure used is shown in Figure 2.
Effect on cell numbers in recipients
Our analysis of the four groups of old mice revealed that
we had successfully introduced young donor T cells into
these animals. We identified the origin of the cells using
anti-CD45.1 staining. Cells of host origin, from the old
mice, would appear to be CD45.1- whilst those of donor
origin from the young mice would be CD45.1+. In all
figures the cells of host origin are represented by filled
circles and those of donor origin by open circles.
Figures 3 and 4 show the numbers of CD3+ and CD3+
CD8+ cells in the spleens and lymph nodes of the old re-
cipients at the time of assay. The results reveal that irre-
spective of the number of cells injected, the overall
numbers of CD3+ T cells in these organs remained
within the same boundaries and were not significantly
different from control animals who received no cells.
Similar results were seen for the CD3+CD8+ T cells.
Analysis of the numbers of donor derived CD3+CD8+
cells in the host revealed that despite there being con-
siderable differences in the number of cells injected
into the host, there was no significant difference in their
final numbers in either the lymph node or the spleens
(Figures 3 and 4). Within the spleen the percentage of
donor CD8+ cells (CD45.1+) of the total CD8+ popula-
tion was extremely similar at 32, 31, and 37% for the re-
cipients of 100, 250 and 500 μl equivalent of blood
respectively. Analysis of the lungs revealed that the
number of CD3+CD8+ T cells was greater in those ani-
mals receiving no transfused cells but similar in those to
whom cells were transfused (Figure 5A).Table 1 Numbers and phenotypes of cells received by
each group of recipient old animals
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Number of CD3+ CD8 + CD62L−
CD44+ cells injected
24,367 61,776 120,120Cellular immune responses
Analysis of the number of virus specific CD3+CD8+Penta-
mer+ T cells in the spleen and lymph nodes revealed that
in each treatment group the numbers of these cells in the
spleens and lymph nodes were similar (Figures 3 and 4).
Moreover where transfusion of cells had occurred there
were similar numbers of virus specific cells of donor and
host origin in these organs. Analysis of the lungs revealed
that the number of CD8+Pentamer+ cells in the lungs were
similar (Figure 5B).
CD107a
Target cells are lysed by effector CD8+ cells through a
process involving release of granules containing gran-
zyme and perforin into the synapse between effector and
target cell. Following this process glycoproteins which
were once found on the lysosomal membrane are ex-
pressed on the surface. One of these proteins is CD107a,
therefore a cell expressing CD107a must have undergone
degranulation following target interaction [21]. Analysis
of the cells in the lungs of animals which received either
250 μl or 500 μl blood equivalent are shown in Figures 4
and 5. The numbers of cells in the lungs were similar.
When we analysed these cells further, in animals which
had received the equivalent of 250 or 500 μl of blood, in
order to determine whether they were of host or donor
origin, the results (Figure 6) showed similar numbers of
each of these in animals.
Viral load
We measured absolute viral load in lung tissue using
real time quantitative PCR (Figure 7), and found that
whilst the viral load amongst the animals receiving PBS
vehicle alone was relatively similar with an average of
3.2 × 104. In contrast the viral load for the treated ani-
mals appears variable. In the recipients of higher doses
half of the animals have viral loads which are less than
2000 and the other half of the readings are closer to 106.
Although we cannot completely discount technical rea-
sons for such variability, it may also indicate the indivi-
dual variability amongst animals either in the cells they
received or the environment provided and whether this
was able to support an effective response.
Discussion
This study reveals that cells from young animals trans-
ferred to an older congenic host can be incorporated
into the peripheral T lymphocyte pool without having a
significant effect on the total number of CD3+ T cells. In
addition, the donor cells within the host are able to
undergo antigen-induced proliferation and differenti-
ation to produce effector CD8 cells, which could con-
tribute to the response to influenza infection in vivo, in
a manner similar to that seen with the host cells. This
Group and 
equivalent 






















Figure 2 A schematic of the experimental design.
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host is not lacking and that effectors could be generated
in an immune response to antigenic challenge. However
the functional response as judged by viral load would ap-
pear to be variable, muted in some animals and showing
greater effectiveness in others.
The total blood volume of an average mouse is 2
millilitres whilst the average human contains approxi-
mately 5 litres [22]. In our experiments we have trans-
ferred the equivalent of 100 μl, 250 μl or 500 μl of blood
from young into old mice, which is the equivalent of
transferring 250, 625 or 1250 ml of blood from a young
human into an older host. Adoptive cell transfer has
been used previously as a form of immunotherapy for
patients with certain cancers or chronic infections. The
therapy normally involves the expansion of specific T
cells ex vivo and their transfer into hosts, which have
been treated to deplete resident T lymphocytes in order
to create “space” for the transferred cells. The treatment
to induce lymphopenia is often associated with un-
wanted toxicity. In these experiments we have trans-
ferred blood derived leukocytes into lymphoreplete hosts
without prior selection or expansion. Entry and survivalCD3+ CD3+ C
Amount (µl) of donor blood injected  Amount (µl) of 
Figure 3 Numbers of T cell subsets in the spleens of individual mice
are CD45.1+ and filled circles (host origin) CD45.1- cells. Solid bars indicate
average numbers of cells of donor origin.of the introduced cells in the resident pool demands
their competition with resident cells for specific niches
and necessary cytokines and is not driven by exogenous
antigen [23,24]. Our adoptively transferred cells were
given 3 weeks before meeting influenza antigen as previ-
ous work indicated that this is the time necessary to
enter the peripheral pool [25,26]. After the introduction
of antigen both resident and transferred cells would be
driven to proliferate, competing for available resources.
Our results reveal that although there was a five-fold dif-
ference between the lowest and the highest number of
cells transferred, at the time of assay there was no major
difference in the numbers of donor cells in the hosts
when compared with the numbers injected. Our experi-
ments would suggest that there appears to be no direct
correlation between the number of cells injected and the
number of cells present within the host at the time of
assay, implying that cell dose was not a critical factor in
incorporation into the peripheral T cell pool.
Failure to correlate initial cell dose with final cell num-
bers suggests considerable expansion from the injected
cells at the lower doses compared with the higher dose.
Our results suggest that in the spleen there was on averageD8+ CD3+ CD8+Pent+
donor blood injected  Amount (µl) of donor blood injected  
within each of the experimental groups. Open circles (donor origin)
average numbers of cells of host origin and dashed bars indicate
CD3+ CD3+ CD8+ CD3+ CD8+Pent+
Amount (µl) of donor blood injected  Amount (µl) of donor blood injected  Amount (µl) of donor blood injected  
Figure 4 Numbers of T cell subsets in the lymph nodes of individual mice within each of the experimental groups. Open circles (donor origin)
are CD45.1+ and filled circles (host origin) represent CD45.1- cells. Solid bars indicate average numbers of cells of host origin and dashed bars
indicate average numbers of cells of donor origin.
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those animals receiving the equivalent of 100 μl of blood
and for those receiving the 250 μl equivalent there was on
average a 50-fold expansion. This is before taking into ac-
count the cells in the lymph nodes and the rest of the im-
mune system. However this is not accompanied by a
dramatic increase in the overall number of cells indicating
that there must be niche competition between cells of
donor and host origin.
The concept that inadequate responses to vaccines are
made in the elderly because of a lack of diversity within
the peripheral T cell repertoire has been common cur-
rency [10]. The size of the αβ T cell repertoire in the
spleens of young mice has been calculated to be in the
region of 2 × 106 clones with approximately 10 cells per
clone [27]. Whilst rejuvenation of the repertoire in older
individuals through reversal of thymic atrophy and in-
creasing thymic output leads to improved responses and
a possible broader repertoire, providing an improved/
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Figure 5 Numbers of CD3+CD8+ T cells (A) and CD8+Pentamer+ T cell
groups. No significant difference (p > 0.05) was found between PBS valuesmay not “fill” the holes in the repertoire. Our results in
this study using a dose escalation of lymphocytes would
suggest that the functional repertoire within the lowest
dose was in the region of 15,200 clones. Either this num-
ber of clones contains the receptor for the A/PR/8 NP
366–374 (ASNENMETM) peptide or else there is consi-
derable cross reactivity within the repertoire which has
been suggested previously [28].
Failure to see significant decline in viral load in the
lungs of all treated animals in the presence of an appa-
rently active CD8 mediated response was unexpected.
This may be related to a host versus graft immune re-
sponse, which is not without precedent having been
reported previously [29]. Indeed some recipient animals
appeared to show structures which resembled abnor-
mally large lymph nodes and our analysis of these re-
vealed they contained cells of host origin the majority of
which were of a memory phenotype (CD62L-CD44+)
and many of them appear to be CD4+ (data not shown).
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s (B) in the left lung of mice within each of the experimental
and any of the treatment groups in either (A) or (B).

















Figure 6 Numbers of CD3+CD8+CD107+Pentamer+ cells in lungs
of individual animals in treatment groups receiving either 250
or 500 μl of blood. Open circles (donor origin) are CD45.1+ and
filled circles (host origin) represent CD45.1- cells. Solid bars indicate
average numbers of cells of host origin and dashed bars indicate
average numbers of cells of donor origin.
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an on-going host versus graft response in the animals.
Conclusions
Transfusion of young donor cells into older congenic
host animals leads to their incorporation into the per-
ipheral T cell pool. The generation of effector cells from
the cell population injected would suggest that they are
contributing to the overall immune response in the ani-
























Figure 7 Absolute qPCR quantification of viral load in lung tissue. Vira
obtain the number of copies of viral RNA per μg of cDNA sample. Columnappear to have no clear overall additional effect on the
hosts response to challenge with influenza virus.
Materials and methods
Mice
C57BL/6 (CD45.2) female mice were maintained by
Charles Rivers Laboratories until they were 22 months
of age. C57BL/6.SJL (CD45.1) female mice were obtained
from Charles Rivers when 6 weeks of age. Both were
sent to the Biological Research Unit where these experi-
ments were undertaken. All experiments were carried out
in accordance with the local rules and regulations and un-
der a project license reviewed by the Open University re-
view board and approval by the Home Office.
Treatment
Young mice
The C57BL/6.SJL (CD45.1) female mice were exsangui-
nated at 6 weeks of age and the blood collected into
tubes containing EDTA as an anticoagulant. Mono-
nuclear cells were isolated by density dependant centri-
fugation, washed by centrifugation and then counted.
These cells were frozen in freezing mixture consisting of
FCS supplemented with 10% DMSO and stored at −150°
C until required.
Old mice
The 22 month old C57Bl/6 female mice were injected in
the tail vein with cells from young (6 week old) female
C57BL6/SJL female mice according to the following
regimes:
Group 1 received the equivalent of 100 μl of blood
Group 2 received the equivalent of 250 μl of blood
Group 3 received the equivalent of 500 μl of blood
Group 4 received saline vehicle alone100-3 250-1 250-2 250-3 250-4 500-1 500-2 500-3 500-4
t (µl) of donor blood injected 
l load detection was performed by qPCR using a standard curve to
s represent average viral copies obtained from triplicate analysis.
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formalin inactivated influenza virus (A/PR/8) receiving
three injections over a 2 week period and then 3 weeks
after the last vaccination the mice were challenged with
approximately 50 pfu of live A/PR/8 influenza virus deliv-
ered intra-nasally. They were monitored over the next
eight days and culled on the ninth day and their tissues re-
moved and analysed. Mice were therefore over 24 months
of age at the time of analysis. Initially each group of mice
contained 5 animals but of the 20 animals which started
the experiment only 16 were analysed as the remaining 4
died at different stages during the procedure.
Cell preparation from lymph nodes, spleen and lung
Axial and mesenteric lymph nodes and spleen were ex-
cised and the organs placed in media consisting of DMEM
and PBS supplemented with 5% FCS. The tissues were
taken to the laboratory at Cranfield where cell suspensions
were made by passing the tissue through a cell strainer
(Becton Dickinson, Oxford, U.K.) into DMEM plus PBS
supplemented with 5% FCS. In the spleen cell suspensions
the erythrocytes were lysed using red cell lysis fluid
(Ortho, Amersham, U.K.), and total number of cells then
counted. The cells were washed by centrifugation and
resuspended in freezing media consisting of FCS with 10%
DMSO and frozen and stored at −150°C until analysed.
For the lung tissues, both lungs were removed and the
cells suspensions made from the left lobe by passing the
lobe through a cell strainer (Becton Dickinson, Oxford,
U.K.) into DMEM plus PBS supplemented with 5% FCS.
The cells were counted and then washed by centrifuga-
tion and frozen in the freezing mixture.
Staining lymph node and spleen cells
These cells were defrosted and washed in DMEM and PBS
supplemented with 5% FCS and approximately 106 cells in
were stained with the following antibody cocktail anti
CD45.1 PE-Cy5 (clone A20), anti-CD8 APC (clone 53–6.7),
anti CD3 FITC (clone 145 2C11) (all from Cambridge Bio-
Sciences) and PE conjugated pentamer specific for anti
H-2Db Influenza A/PR/8 NP 366–374 (ASNENMETM)
peptide (ProImmune). In addition a further 106 cells
were stained with the isotype control for each antibody
or the pentamer control. For staining the cells were
incubated in a volume of 100 μl for approximately 45 -
minutes at 4°C in the wells of a round bottomed 96 well
plate before being washed by centrifugation and
resuspended in 1% solution of paraformaldehyde in
PBS. Analysis was carried out on an Accuri C6 flow
cytometer.
Staining lung cells
These cells were defrosted and washed in DMEM and
PBS supplemented with 5% FCS and approximately 106cells in were stained with the following antibody cocktail
anti CD45.1 PE-Cy5 (clone A20), anti-CD8 APC (clone
53–6.7), anti CD3 FITC (clone 145 2C11) and PE conju-
gated pentamer specific for anti H-2Db Influenza A/PR/
8 NP 366–374 (ASNENMETM) peptide. A separate ali-
quot of 106 cells was stained with the following antibody
cocktail anti CD45.1 PE-Cy5 (clone A20), anti-CD8 APC
(clone 53–6.7), anti CD107a FITC (clone H4A3) and PE
conjugated pentamer specific for anti H-2Db Influenza
A/PR/8 NP 366–374 (ASNENMETM) peptide. In ad-
dition two further lots of 106 cells were stained with the
isotype control for each antibody or the pentamer con-
trol where appropriate. Staining was carried out as de-
scribed above. Analysis was carried out on an Accuri C6
flow cytometer.
Staining blood leukocytes from young animals
The leukocytes from the C57BL/6.SJL young animal
were stained with the following antibody cocktail anti-
CD44 APC (clone IM7) anti-CD62L PerCP (clone Mel 14)
anti CD3 FITC (clone 145 2C11) and either anti-CD4 PE
or anti-CD8 PE. The staining process was as described
above. Analysis was carried out on an Accuri C6 flow
cytometer.
Viral load
To determine viral load, 20-30 mg of frozen lung tissue
was suspended in buffer RTL (Qiagen), disrupted for
20 sec at 6500 rpm with CK28 ceramic beads using the
Percellys 24 tissue homogenizer (Stretton Scientific).
RNA extraction was performed on the supernatant
according to the manufacturer’s guidelines including
treatment with DNAse1 prior to elution (RNeasy Qiagen).
RNA integrity was quantified using the BioRad Experion.
Samples with RQI values of 7.5 and above were used for
further analysis. RNA concentrations were determined
using the Picodrop and normalised to 1000 ng/10 μl for
subsequent MultiScribe™ reverse transcriptase reaction to
generate cDNA using the High Capacity Reverse tran-
scriptase kit (Applied Biosystems). Absolute quantification
of viral copy number was performed using a log linear
101-107 standard curve using a viral RNA plasmid con-
struct of region 855-999 bp of Segment 6 neuraminidase
(NA) gene [30]. qPCR reactions were set up in triplicate
using the QIAgility and performed on the Rotorgene Q
(Qiagen). Standard cycling conditions were hot start at 95°C
for 15 mins, and 40 cycles of 95°C for 15 sec, 55°C for
30 sec, and 72°C for 30 sec. The 10 μl reaction mix com-
prised of 5 μl of 2×Quantitect SYBR (Qiagen), 0.5 μM for-
ward (855–874) ATTTGCCTATGAGACCGATGCT and
reverse (975–999) AGGATGGGGGCTGTGACC [30],
2 μl of cDNA equivalent to 100 ng and 2 μl of water. The
specificity of the qPCR product was validated by melt
curve analysis.
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